The Evolution of Ketamine Treatment


Steven P. Levine, MD, a board-certified psychiatrist and therapist who currently practices in Princeton, NJ, details the history of ketamine from its original development as a general anesthetic through its clinical use today as an antidepressant in patients presenting treatment-resistant depression.
According to Levine, ketamine “cut its teeth” as a battlefield anesthetic in the Vietnam War, where it was known as a “buddy drug” because it could be quickly and safely administered by a soldier’s “buddy in the field.”
However, Levine points out that ketamine’s mechanism had already been studied as an anti-depressant throughout the decade leading up to the war. Even so, it wasn’t until the late 1990s that an early pilot study showed “remarkable results” with the indication, and though ketamine has had a “long research track record” since that initial study, the drug “really wasn’t used clinically outside of the research setting until the past few years.”
Despite the drug’s late clinical adoption, Levine says ketamine is a viable option for treatment-resistant depression because it has “a very different mechanism and a very different pattern of effect and group of side effects” compared to typical antidepressants.

Most Popular

Recommended Reading

Tenofovir alafenamide, which results in 90% lower circulating plasma tenofovir than standard tenofovir disoproxil fumarate, is associated with similar virologic response rates as the standard regimen, but with an improved safety profile.
Combination treatment with daclatasvir and asunaprevir plus interferon/ribavirin had high success rates in a 24-week clinical trial for treatment of hepatitis C in patients coninfected with HIV.
An interferon/ribavirin-free pill that combines two drugs to treat patients with certain genotypes of hepatitis C who are also infected with HIV was found to be highly effective in a 12-week trial, clearing the hepatitis C virus from almost all the patients involved.
Novel second-generation HIV-1 maturation inhibitor shows favorable antiviral activity and safety profile in HIV-1, subtype B-infected subjects
$vacMongoViewPlus$ $vAR$